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non-spine/non-hip fracture, parental history of hip fracture 
and current smoking were the most commonly observed.
Conclusions Our study showed that more that the half of 
postmenopausal women aged 50 and older in Italy has osteo-
porosis on the basis of the NBHA criteria. There is a relevant 
high risk of femur fracture, as assessed by the  FRAX® and 
DeFRA and previous fracture, parental history of hip frac-
ture and current smoking are the most common risk factors. 
The data should be considered particularly in relation to the 
need to increase prevention strategies on modifiable risk fac-
tors and therapeutic intervention.
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Abstract 
Purpose The study was aimed at evaluating the prevalence 
of osteoporosis, defined by BMD and the National Bone 
Health Alliance (NBHA) criteria, and the prevalence of 
clinical risk factors for fractures in Italian postmenopausal 
women.
Methods This is a cross-sectional, multicenter, cohort 
study evaluating 3247 postmenopausal women aged ≥ 50 
and older in different areas of Italy in the period 2012–2014. 
All the participants were evaluated as far as anthropomet-
rics; questionnaires for  FRAX® and DeFRA calculation 
were administered and bone mineral density was measured 
at lumbar spine, femoral neck and total hip by DXA.
Results The prevalence of osteoporosis, as assessed by 
BMD and NBHA criteria was 36.6 and 57%, respectively. 
Mean ± SD values of  FRAX® and DeFRA were: 10.2 ± 7.3 
and 11 ± 9.4 for major fractures, and 3.3 ± 4.9 and 3.9 ± 5.9 
for hip fractures, respectively. Among clinical risk factors 
for fracture, the presence of previous fracture, particularly 
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Introduction
Osteoporosis is defined on the basis of reduced bone min-
eral density (BMD) and altered skeletal microarchitecture, 
with consequent increased risk for fracture. The use of dual-
energy X-ray absorptiometry (DXA) to measure BMD is 
the universally accepted method to diagnose osteoporosis, 
but recent recommendations pointed out that the diagnos-
tic criteria should also include the presence of low trauma 
fractures and/or an elevated fracture risk [1–6]. In particular, 
the National Bone Health Alliance (NBHA) Working Group 
recommended that postmenopausal women and men over 
50 should be diagnosed to have osteoporosis based on DXA 
T-score ≤ −2.5 and on the presence of low-trauma hip frac-
ture (independently of BMD) or in presence of osteopenia by 
BMD and low-trauma vertebral, proximal humerus, pelvis, 
or distal forearm fracture in some cases [5].
The identification of risk factors contributing to bone fra-
gility and fractures has led in the last decade to the defini-
tion of models and algorithms for the assessment of 10-year 
individuals’ risk of fracture [7]. Among BMD-independent 
factors, clinical risk factors are of utmost importance in 
the identification of patients at high risk and are routinely 
employed in clinical practice, particularly in the  FRAX® 
calculation [7]. The presence of an elevated fracture risk 
as assessed by  FRAX® has been included in the defini-
tion of osteoporosis (10 year hip fracture risk of ≥ 3% or 
major osteoporotic fracture risk of ≥ 20%) [5]. The derived 
 FRAX® algorithm, DeFRA was developed by the Italian 
Society for Osteoporosis, Mineral Metabolism, and Skeletal 
Diseases (SIOMMMS) with the aim of further increase the 
sensitivity of fracture risk assessment and its validation is 
still ongoing [8, 9]. It can be used only in postmenopausal 
women aged 50–90 and includes a deeper and more accurate 
analysis of the “classical” clinical risk factors included in 
the  FRAX® related to previous fractures, cigarette smok-
ing, alcohol, corticosteroid use and rheumatic diseases, as 
well as the inclusion of either lumbar spine or neck BMD 
[8]. The rationale of DeFRA derived from epidemiological 
and cohort studies showing a strong association between the 
quantification of risk factors and fractures [10–15].
Epidemiological studies showed different data on the 
prevalence of osteoporosis and fragility fractures [16–18]. 
The disparity can be explained based on differences among 
populations from various geographical areas, differences 
in the socioeconomic status and in the ethnicity. Addition-
ally, secular trends in the incidence of osteoporotic fracture 
has been observed over several decades [16–18]. Recent 
data from US reported that 10.3% of adults (10.2 million) 
50 years and older in the NHANES population (2005–2010) 
have osteoporosis when the diagnosis is made using lumbar 
spine and femoral neck BMD, with a 43.9% prevalence of 
low bone mass [19]. The application of the NBHA criteria to 
the NHANES 2005–2008 data showed a 16% prevalence of 
osteoporosis in men and 29.9% in women aged 50 and older 
[20]. Data on the prevalence of osteoporosis in the Italian 
population are limited and rely mainly on the evaluation 
of osteoporosis in selected populations [21, 22]. The only 
cross-sectional study performed in the general population 
applied the quantitative heel ultrasound technology to assess 
the prevalence of osteoporosis, reporting a 18.5% rate of 
osteoporosis and 44.7% of osteopenia in women aged 40–79 
[23]. However, as far as risk factors, Bonaccorsi et al. [22] 
found the highest prevalence of smoking (12.9), parental 
history of hip fracture (11.2%) and secondary osteoporo-
sis (10.3%) among women aged 50–90 referring to a single 
tertiary care center. No study so far has dealt with the issue 
of prevalence of osteoporosis, as evaluated by BMD and 
NBHA criteria, nor has assessed the prevalence of clinical 
risk factors for fractures in the Italian population. We report 
data from a cross-sectional, multicenter, cohort study pri-
marily aimed at addressing these issues, together with the 
evaluation of both  FRAX® and DeFRA algorithms and their 
sensitivity in predicting fracture risk.
Methods
We studied 3247 postmenopausal women aged 50 and older 
in different areas of Italy in the period 2012–2014. Eight 
referring Centers for the study of Metabolic Bone Disease 
were involved in 7 different cities allocated in the north, 
center and south of the country: Brescia (53 women), Foggia 
(73), Genoa (1016), Rome (441), Siena (173), Turin (69), 
Verona (471 and 951). The general practitioners connected 
to the osteoporosis center directly contacted all the post-
menopausal women aged ≥ 50 referred to their primary care 
clinic and referred them to the center. The original number 
of women contacted was 4330; the response rate was, there-
fore, of 75%. Clinical characteristics of women who refused 
to participate the study were not different from those who 
participated. All the participants were evaluated as far as 
anthropometrics; body weight was measured to the near-
est 0.01 kg using an electronic load cell scale, and stand-
ing height was measured with a fixed stadiometer. BMI was 
calculated as body weight (kilograms) divided by height 
(meters squared). Subjects were administered the ques-
tionnaires for  FRAX® and DeFRA calculation and includ-
ing: demographic data, previous fracture (yes/no; spine, 
femur—specifying if 1, 2 or more; non-spine non-femur 
after 50 years of age—specifying if 1, 2 or more), parental 
history of femur fracture, smoking (yes/no; < 10 or ≥ 10 
cigarettes/day), corticosteroids use (yes/no; > 2.5 < 5 mg/
day or > 5 mg/day), rheumatoid arthritis, alcohol (yes/no) 
and secondary causes of osteoporosis.
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Bone mineral density was measured at the lumbar spine 
(L1–L4), femoral neck (FN), and total hip (TH) by DXA 
(QDR-4500; Hologic Inc. and Lunar Prodigy, GE Health-
care) in any center. The DXA machines were cross-cali-
brated at the beginning of the study using the same spine 
phantom scanned ten times in any center. All the centers 
performed machine calibration daily. Lumbar vertebrae were 
excluded from BMD measurement if degenerative diseases, 
fusions, or fractures were recorded at the study visit or noted 
in the image. The hip was not scanned when a positive his-
tory of fracture or surgery was present. Both lumbar verte-
brae and/or the femur were excluded from the scan when any 
of the following was present: removable or non-removable 
objects (e.g., implants, prosthesis), excessive X-ray “noise” 
due to obesity, positioning issues, self-report of an imaging 
procedure using contrast material in the previous 7 days, 
participant movement during the scan, and, in the case of 
femur scans, panniculus. Lumbar spine and femur BMD 
data were converted to the Hologic based data using the 
standardization approach described by Genant et al. [24] to 
provide compatibility of DXA results obtained on different 
scanners. BMD values of healthy premenopausal women 
aged 20–45 and of healthy men aged 20–40 were defined as 
the peak bone mass and used for the calculation of T-score 
at the lumbar spine [25]. The reference group for T-score 
calculation for femoral neck consisted of 20–29 aged non-
Hispanic white subjects of both sexes from NHANES III, as 
recommended by the WHO [26, 27]. These reference values 
were used because the BMD values observed in the first 3 
decades in healthy Italian women and men are virtually iden-
tical to those of the NHANES study [25]. All DXA scans 
were centrally read by the same radiologist (DD).
The assessment of the individual 10-year fracture risk 
for major fractures and hip fractures was done using the 
clinical risk factors and femoral neck BMD and T-score. 
The  FRAX® tool for Italy (http://www.shef.ac.uk/FRAX) 
and DeFRA (https://defra-osteoporosi.it) were used.
Osteoporosis was defined by T-score ≤ 2.5 at any of the 
two skeletal sites. As per the NBHA recommendations, sub-
jects were defined to have osteoporosis also in case of low-
trauma hip fracture (independently of BMD) or osteopenia 
(T-score ≤ −1 > −2.5) at any of the two skeletal sites in 
association with at least one major low-trauma fracture (ver-
tebral, proximal humerus, pelvis, or distal forearm) occurred 
after the menopause or if they have the 10-year probability 
for either major or hip fracture ≥ 20 and ≥ 3%, respectively, 
based on  FRAX® [5]. Finally, subjects with DeFRA values 
≥ 20% for major fractures and ≥ 3% for hip fractures were 
defined as having osteoporosis.
Written informed consent was obtained from all partici-
pants after full explanation of the study details. The protocol 
was approved by the Ethics Committees of any of the Center 
participating in the study.
Statistical analysis
Descriptive statistics are expressed as mean ± SD. Since 
some of the data may show an asymmetric distribution, first, 
second and third quartiles have been also calculated. The 
Wilcox test for paired samples was used to compared data 
from  FRAX® and DeFRA calculation. The prevalence of 
osteoporosis was assessed on the basis of the NBHA cri-
teria [5] and the DeFRA criterion in the entire cohort and 
expressed as percentage. The prevalence of osteopenia was 
also calculated. The prevalence of the clinical risk factors 
included in the  FRAX® and DeFRA was calculated in the 
entire cohort.
The association between values derived from  FRAX® 
and DeFRA was assessed using Spearman’s rank correla-
tion coefficient. Inter-criteria agreement between the two 
algorithms was assessed using Cohen’s kappa statistic.
p values < 0.05 were considered significant and the R 
package (version 3.02) was used for statistical calculations.
Results
Table 1 shows mean values ± SD of demographic, BMD, 
 FRAX® and DeFRA data, as well as the prevalence of major 
osteoporotic fractures and osteoporosis in the entire cohort. 
We observed a significant difference between  FRAX® and 
DeFRA data using Wilkcox test (p < 0.0001). We observed 
a 33% and 37.3% of the cohort having  FRAX® and DeFRA 
values ≥ 3%, respectively.
The prevalence of osteoporosis, as assessed by BMD cri-
teria was 36.6% (Table 1). In particular, 28.4% of subjects 
had lumbar spine osteoporosis and 16.2% had osteoporosis 
at the femoral neck and 8.2% had both lumbar spine and 
femoral neck osteoporosis. The prevalence of osteopenia 
was 52%.
According to the NBHA criteria, the prevalence of 
osteoporosis was assessed on the basis of the presence of 
low-trauma femur fracture and independently on BMD 
and was 2.5%, and in case of osteopenia and at least one 
major low-trauma fracture and resulted in 9.3% of subjects 
(Table 1). The  FRAX® and DeFRA criteria for the definition 
of osteoporotic patients was also applied and showed a 32.6 
and 37.4% prevalence of osteoporosis in our cohort, respec-
tively (Table 1). Taking into account any of the aforemen-
tioned criteria, the general prevalence of osteoporosis in our 
cohort was 57% (Table 1). The prevalence of osteoporosis, 
as defined by any of the aforementioned criteria and accord-
ing to age class is reported in Fig. 1. We observed a signifi-
cant difference in the prevalence of osteoporosis between 
the north (50%) and the center-south of the country (59%; 
p < 0.0001).
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Table 2 reports the prevalence of clinical risk factors 
included in  FRAX® and DeFRA calculation. As shown, 
the presence of previous fracture, particularly non-spine/
non-hip fracture, parental history of hip fracture and the 
current smoking were the most common risk factors in 
our cohort.
We found a significant association between  FRAX® 
and DeFRA as far as risk for major fracture (r = 0.920, 
p < 0.0001) and for hip fracture (r = 0.971, p < 0.0001). 
There was a high concordance between the two algo-
rithms in the evaluation of both major fracture and hip 
fracture risk resulting in a Cohen’s kappa equal to 0.834 
(p < 0.0001) which indicates an almost perfect concord-
ance between the two criteria.
Discussion
Osteoporosis is a well-recognized major health problem 
worldwide and the burden of the disease is mostly associated 
with the occurrence of hip and vertebral fracture [28]. Stud-
ies on the prevalence of osteoporosis, fractures, and risk fac-
tors for fracture have been conducted in different countries, 
but none in Italy. In this context, our study reported for the 
first time the prevalence of osteoporosis in Italian postmeno-
pausal women aged 50 and older and focused not only on 
the BMD measurement, but also on the assessment of other 
factors defining fracture risk and recently included in the 
definition of osteoporosis [5]. We observed a 36.6% preva-
lence of osteoporosis and 51% of osteopenia, accounting for 
Table 1  Characteristics of the 
cohort of women: mean ± SD 
[median (25° percentile; 75° 
percentile)]
*p < 0.0001 compared to DeFRA using Wilkcox test; #General prevalence calculated considering any of 
the NBHA criteria
Characteristics n = 3247
Age (years) 65.7 ± 8.5 [66 (59; 72)]
Weight (kg) 64.8 ± 12 [63 (56; 72)]
Height (cm) 157 [156 (152; 160)]
BMI (kg/m2) 26.5 ± 4.8 [25,8 (23; 29)]
L1-L4 BMD (g/cm2) 0.856 ± 0.140 [0.839 (0.762; 0.939)]
T-score − 1.7 ± 1.3 [− 1.9 (− 2.6; − 1.0)]
FN BMD (g/cm2) 0.669 ± 0.105 [0.660 (0.599; 0.732)]
T-score − 1.6 ± 0.9 [− 1.7 (− 2.25; − 1.1)]
TH BMD (g/cm2) 0.794 ± 0.119 [0.789 (0.718; 0.869)]
T-score − 1.2 ± 1 [− 1.3 (− 1.8; − 0.6)]






FRAX® without Neck BMD (%)
 Major fractures 11.4 ± 8.8 [8.9 (5.2; 14.7)]
 Hip fractures 4.5 ± 6.3 [2.3 (0.9; 5.5)]
FRAX® with Neck BMD (%)*
 Major fractures 10.2 ± 7.3 [8.2 (5.1; 12.8)]
 Hip fractures 3.3 ± 4.9 [1.7 (0.7; 3.9)]
DeFRA (%)
 Major fractures 11 ± 9.4 [8.2 (5.5; 12.9)]
 Hip fractures 3.9 ± 5.9 [2 (0.8; 4.6)]
Prevalence of osteoporosis (% of the entire population)
 By NBHA criteria 57#
 BMD 36.6
 Low-trauma femur fracture 2.5
 Osteopenia + one major low-trauma fracture 9.3
 FRAX® 32.6
 By DeFRA 37.4
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87% of subjects with low bone mass, as assessed by DXA. 
This figure is particularly relevant, especially in relation with 
data from other countries [19, 29]. Data collected in over 50 
million US women from 2005 to 2010 showed a prevalence 
of osteoporosis of 15.5%, with 8.2% of the women having 
femoral neck osteoporosis after adjusting for age, sex, and 
ethnic distribution of the US population [19]. Notwithstand-
ing the differences between the studies, mostly related to 
differences in the age and ethnicity composition between 
the two cohorts, our results further confirm the presence of 
international disparity in the rate of osteoporosis and osteo-
porotic fracture [30]. Data from our study are indeed in line 
with those from other Italian cohorts showing a high preva-
lence of low bone mass among postmenopausal women [22]. 
Several factors should be taken into account in the evaluation 
of these findings, mostly related to genetic, environmental 
and lifestyle determinants. Given to the complex pathogen-
esis of the disease [31], difference in the genetic susceptibil-
ity to osteoporosis and fracture across countries is indeed 
advocated as one of the main mechanisms, having bone mass 
and bone architecture, as well as other factors associated 
with fracture risk strong genetic basis [32–34]. Furthermore, 
Fig. 1  Prevalence of osteopo-
rosis (% of the entire cohort) 
defined by the presence of at 
least one of the NBHA criteria 
and distributed according to 
age class
Table 2  Prevalence of clinical risk factors included in  FRAX® and 
DeFRA
Data are expressed as percentage (%) of subjects in the entire cohort
Clinical risk factor FRAX® DeFRA
Previous fractures (%) 31.6 31.6
Spine and hip (%) – 8
 1 – 7.7
 > 1 – 0.3
Non-spine/non-hip (%) – 27.2
 1 – 23.6
 > 1 – 3.6
Parental history of hip fractures (%) 14.6 14.6
Current smoking (%) 11.7 11.7
 < 10 cigarettes/day – 6.4
 > 10 cigarettes/day – 5
Glucocorticoids (%) 6 6
 > 2.5 < 5 mg/day – 4.4
 > 5 mg/day – 1.3
Rheumatoid arthritis (%) 4.5 4.5
 Secondary osteoporosis (%) 10.2 10.2
 Alcohol (%) 1.8 1.8
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other evidence suggests that difference in demographic fea-
tures, as well as in some of the indicators of development 
in a given country, life expectancy and the socioeconomic 
status correlate with the different hip fracture rates across 
countries [33]. As far as data on fractures, the rate of 23% for 
major osteoporotic fractures is in line with previous reports 
from other Italian cohorts [22, 35]. Conversely, data from 
the NHANES population showed lower rate of hip, spine 
and distal forearm fractures in women (1.4–3.3% depending 
on age range) compared to our study and previous studies in 
Italian cohorts [20, 22]. In addition, the high rate of hypo-
vitaminosis D commonly observed in observational studies 
and the almost absent habit of using fortified foods in Italy 
(as it is the case in other countries) should be considered 
as other important risk factors accounting for international 
difference in the epidemiology of osteoporosis and fracture 
[36, 37]. Beyond the aforementioned genetic and environ-
mental factors, these data could also be interpreted on the 
basis of different levels of awareness on osteoporosis and 
fractures between the different populations, with a lower 
number of women in Italy performing screening tests and 
coming to attention of specialized centers before the fra-
gility fracture occurs. Strategies aimed at reinforcing the 
primary prevention in the field of bone fragility, particularly 
among postmenopausal women, are, therefore, warranted on 
a National basis by designing prevention programs involving 
particularly primary healthcare providers. In this context, the 
use of algorithms for the assessment of fracture risk repre-
sents a valid instrument, as shown in our study. We observed 
indeed high mean values of both  FRAX® and DeFRA as far 
as the probability of femur fracture that is comparable to 
what reported in a previous study from other Italian cohorts 
[38]. Notwithstanding the limited data demonstrating that 
patients with hip fracture risk ≥ 3% that represents the theo-
retical threshold for defining an elevated fracture risk [5], 
will positively respond to osteoporotic treatment in terms 
of femur fracture reduction, these data account for the need 
of higher attention for this complication, particularly from 
a therapeutic point of view [39].
Notwithstanding the presence of mean DXA values in 
the range of osteopenia at femoral neck, the evaluation of 
the algorithms gives a further contribution in the identifi-
cation of women who need treatment and/or intervention 
on modifiable factors and/or a strict follow-up because at 
medium–high risk for fracture. As far as risk factors, our 
study confirmed what previously observed in other Italian 
cohorts showing how previous fragility fracture, parental 
history of fracture, smoking and secondary osteoporosis rep-
resent the two most frequent factors after history of fracture 
[22, 35].
The presence of strong association and concordance 
between  FRAX® and DeFRA accounts for a high value of 
the derived algorithm in the assessment of fracture risk. 
The higher value of DeFRA compared to  FRAX® further 
confirms the possibility of using DeFRA in specific sub-
groups of patients [22]. Additionally, our results suggest the 
possibility of further developments of DeFRA by including 
other covariates that demonstrated to strongly influence frac-
ture risk [40]. Recent data from a cohort study in Manitoba, 
Canada have indeed demonstrated as parental hip fracture 
occurring at the age ≥ 80 has no significant association with 
the risk of major osteoporotic fracture, while the association 
was strong particularly when fracture in the parent occurred 
before the age of 70 [40]. The inclusion of age of the paren-
tal hip fracture in the DeFRA calculation would, therefore, 
be an interesting point for future research.
Limitations of our study pertain its observational nature 
and, therefore, the absence of any follow-up data in our 
cohort that would have given the possibility to assess the 
sensitivity and predictive value of the algorithms, particu-
larly the DeFRA. In addition, we have data only on clinical 
vertebral fractures and can hypothesize that this complica-
tion of the disease has been underestimated by the current 
data. We also acknowledge that it is not possible to exclude 
a selection bias on the basis of a possible higher sensitivity 
to the issue of osteoporosis by those women who decided to 
participate for many reasons (experienced fracture, family 
history of fracture, etc.). Nonetheless, this is the first cohort 
study in Italy that evaluated the prevalence of osteoporosis 
by DXA and by the use of the NBHA criteria and reported 
the prevalence of the major clinical osteoporotic fractures 
and the main risk factors for fracture.
In conclusion, our study showed that more that the half 
of postmenopausal women aged 50 and older in Italy have 
osteoporosis on the basis of the most recent criteria. Addi-
tionally, there is a high rate of major osteoporotic fractures 
and relevant high risk of femur fracture, as assessed by the 
 FRAX® and DeFRA algorithm. We believe that our results 
should be considered particularly in relation to the need to 
increase prevention strategies on modifiable risk factors and 
therapeutic intervention.
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